{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:37:32Z","timestamp":1787168252985,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1038\/s41401-022-01025-y","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T03:54:54Z","timestamp":1670298894000},"page":"1149-1160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Porcupine inhibitor CGX1321 alleviates heart failure with preserved ejection fraction in mice by blocking WNT signaling"],"prefix":"10.1038","volume":"44","author":[{"given":"Hao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-xun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-mei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-kang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-ji","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-zhong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-ling","family":"Shou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong-shu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-jun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songzhu Michael","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-yu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Eric","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"key":"1025_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev-med-041316-090654","volume":"69","author":"JD Gladden","year":"2018","unstructured":"Gladden JD, Chaanine AH, Redfield MM. Heart failure with preserved ejection fraction. Annu Rev Med. 2018;69:65\u201379.","journal-title":"Annu Rev Med"},{"key":"1025_CR2","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","volume":"141","author":"SS Virani","year":"2020","unstructured":"Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020;141:e139\u2013e596.","journal-title":"Circulation"},{"key":"1025_CR3","first-page":"181","volume":"371","author":"MA Pfeffer","year":"2014","unstructured":"Pfeffer MA, Pitt B, McKinlay SM. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;371:181\u20132.","journal-title":"N Engl J Med"},{"key":"1025_CR4","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456\u201367.","journal-title":"N Engl J Med"},{"key":"1025_CR5","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777\u201381.","journal-title":"Lancet"},{"key":"1025_CR6","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451\u201361.","journal-title":"N Engl J Med"},{"key":"1025_CR7","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609\u201320.","journal-title":"N Engl J Med"},{"key":"1025_CR8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1161\/CIRCULATIONAHA.119.041886","volume":"141","author":"SJ Shah","year":"2020","unstructured":"Shah SJ, Borlaug BA, Kitzman DW, McCulloch AD, Blaxall BC, Agarwal R, et al. Research priorities for heart failure with preserved ejection fraction: national heart, lung, and blood institute working group summary. Circulation. 2020;141:1001\u201326.","journal-title":"Circulation"},{"key":"1025_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jacc.2020.05.072","volume":"76","author":"J Cunningham","year":"2020","unstructured":"Cunningham J, Claggett B, O\u2019Meara E, Prescott M, Pfeffer M, Shah S, et al. Effect of sacubitril\/valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF. J Am Coll Cardiol. 2020;76:503\u201314.","journal-title":"J Am Coll Cardiol"},{"key":"1025_CR10","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1093\/eurheartj\/ehy301","volume":"39","author":"CSP Lam","year":"2018","unstructured":"Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J. 2018;39:2780\u201392.","journal-title":"Eur Heart J"},{"key":"1025_CR11","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1093\/eurheartj\/ehw241","volume":"37","author":"BA Borlaug","year":"2016","unstructured":"Borlaug BA, Kane GC, Melenovsky V, Olson TP. Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction. Eur Heart J. 2016;37:3293\u2013302.","journal-title":"Eur Heart J"},{"key":"1025_CR12","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1161\/CIRCULATIONAHA.114.009625","volume":"131","author":"SF Mohammed","year":"2015","unstructured":"Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015;131:550\u20139.","journal-title":"Circulation"},{"key":"1025_CR13","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1161\/01.CIR.0000017264.66561.3D","volume":"105","author":"J D\u00edez","year":"2002","unstructured":"D\u00edez J, Querejeta R, L\u00f3pez B, Gonz\u00e1lez A, Larman M, Mart\u00ednez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002;105:2512\u20137.","journal-title":"Circulation"},{"key":"1025_CR14","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1080\/13543776.2021.1940138","volume":"31","author":"VG Goswami","year":"2021","unstructured":"Goswami VG, Patel BD. Recent updates on Wnt signaling modulators: a patent review (2014-2020). Expert Opin Ther Pat. 2021;31:1009\u201343.","journal-title":"Expert Opin Ther Pat"},{"key":"1025_CR15","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.16966\/2472-6990.111","volume":"2","author":"D Bastakoty","year":"2016","unstructured":"Bastakoty D, Saraswati S, Joshi P, Atkinson J, Feoktistov I, Liu J, et al. Temporary, systemic inhibition of the WNT\/\u03b2-Catenin pathway promotes regenerative cardiac repair following myocardial infarct. Cell Stem Cells Regen Med. 2016;2:2472\u201381.","journal-title":"Cell Stem Cells Regen Med"},{"key":"1025_CR16","first-page":"e923025","volume":"26","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Liu H, Li Y, Tian J, Deng S. Wnt-C59 attenuates pressure overload-induced cardiac hypertrophy via interruption of Wnt pathway. Med Sci Monit. 2020;26:e923025.","journal-title":"Med Sci Monit"},{"key":"1025_CR17","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.jacc.2020.08.061","volume":"76","author":"L Adamo","year":"2020","unstructured":"Adamo L, Yu J, Rocha-Resende C, Javaheri A, Head RD, Mann DL. Proteomic signatures of heart failure in relation to left ventricular ejection fraction. J Am Coll Cardiol. 2020;76:1982\u201394.","journal-title":"J Am Coll Cardiol"},{"key":"1025_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.metabol.2015.10.013","volume":"65","author":"H Tao","year":"2016","unstructured":"Tao H, Yang JJ, Shi KH, Li J. Wnt signaling pathway in cardiac fibrosis: New insights and directions. Metabolism. 2016;65:30\u201340.","journal-title":"Metabolism"},{"key":"1025_CR19","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1242\/jcs.259383","volume":"134","author":"J Yu","year":"2021","unstructured":"Yu J, Liao PJ, Xu W, Jones JR, Everman DB, Flanagan-Steet H, et al. Structural model of human PORCN illuminates disease-associated variants and drug-binding sites. J Cell Sci. 2021;134:624\u201336.","journal-title":"J Cell Sci"},{"key":"1025_CR20","doi-asserted-by":"publisher","first-page":"105532","DOI":"10.1016\/j.phrs.2021.105532","volume":"167","author":"K Shah","year":"2021","unstructured":"Shah K, Panchal S, Patel B. Porcupine inhibitors: Novel and emerging anti-cancer therapeutics targeting the Wnt signaling pathway. Pharmacol Res. 2021;167:105532.","journal-title":"Pharmacol Res"},{"key":"1025_CR21","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1016\/j.bbadis.2018.07.035","volume":"1864","author":"J Jiang","year":"2018","unstructured":"Jiang J, Lan C, Li L, Yang D, Xia X, Liao Q, et al. A novel porcupine inhibitor blocks WNT pathways and attenuates cardiac hypertrophy. Biochim Biophys Acta Mol Basis Dis. 2018;1864:3459\u201367.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"1025_CR22","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1042\/CS20171256","volume":"131","author":"D Yang","year":"2017","unstructured":"Yang D, Fu W, Li L, Xia X, Liao Q, Yue R, et al. Therapeutic effect of a novel Wnt pathway inhibitor on cardiac regeneration after myocardial infarction. Clin Sci (Lond). 2017;131:2919\u201332.","journal-title":"Clin Sci (Lond)"},{"key":"1025_CR23","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1161\/CIRCULATIONAHA.109.883777","volume":"121","author":"GA Silberman","year":"2010","unstructured":"Silberman GA, Fan TH, Liu H, Jiao Z, Xiao HD, Lovelock JD, et al. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation. 2010;121:519\u201328.","journal-title":"Circulation"},{"key":"1025_CR24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","volume":"568","author":"GG Schiattarella","year":"2019","unstructured":"Schiattarella GG, Altamirano F, Tong D, French KM, Villalobos E, Kim SY, et al. Nitrosative stress drives heart failure with preserved ejection fraction. Nature. 2019;568:351\u20136.","journal-title":"Nature"},{"key":"1025_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.yjmcc.2017.10.006","volume":"114","author":"M Schnelle","year":"2018","unstructured":"Schnelle M, Catibog N, Zhang M, Nabeebaccus AA, Anderson G, Richards DA, et al. Echocardiographic evaluation of diastolic function in mouse models of heart disease. J Mol Cell Cardiol. 2018;114:20\u20138.","journal-title":"J Mol Cell Cardiol"},{"key":"1025_CR26","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/CIRCRESAHA.120.317933","volume":"128","author":"Y Deng","year":"2021","unstructured":"Deng Y, Xie M, Li Q, Xu X, Ou W, Zhang Y, et al. Targeting mitochondria-inflammation circuit by beta-hydroxybutyrate mitigates HFpEF. Circ Res. 2021;128:232\u201345.","journal-title":"Circ Res"},{"key":"1025_CR27","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1093\/eurheartj\/ehaa878","volume":"42","author":"L Li","year":"2021","unstructured":"Li L, Fu W, Gong X, Chen Z, Tang L, Yang D, et al. The role of G protein-coupled receptor kinase 4 in cardiomyocyte injury after myocardial infarction. Eur Heart J. 2021;42:1415\u201330.","journal-title":"Eur Heart J"},{"key":"1025_CR28","doi-asserted-by":"crossref","unstructured":"Dzia\u0142o E, Rudnik M, Koning RI, Czepiel M, Tkacz K, Baj-Krzyworzeka M, et al. WNT3a and WNT5a transported by exosomes activate WNT signaling pathways in human cardiac fibroblasts. Int J Mol Sci. 2019;20:1436\u201351.","DOI":"10.3390\/ijms20061436"},{"key":"1025_CR29","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/cphy.c140060","volume":"5","author":"KC Hermans","year":"2015","unstructured":"Hermans KC, Blankesteijn WM. Wnt signaling in cardiac disease. Compr Physiol. 2015;5:1183\u2013209.","journal-title":"Compr Physiol"},{"key":"1025_CR30","doi-asserted-by":"crossref","unstructured":"Withaar C, Lam CSP, Schiattarella GG, de Boer RA, Meems LMG. Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models. Eur Heart J. 2021;42:4420\u201330.","DOI":"10.1093\/eurheartj\/ehab389"},{"key":"1025_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00840-w","volume":"8","author":"FL Xiang","year":"2017","unstructured":"Xiang FL, Fang M, Yutzey KE. Loss of beta-catenin in resident cardiac fibroblasts attenuates fibrosis induced by pressure overload in mice. Nat Commun. 2017;8:712.","journal-title":"Nat Commun"},{"key":"1025_CR32","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/164_2016_56","volume":"243","author":"V Stylianidis","year":"2017","unstructured":"Stylianidis V, Hermans KCM, Blankesteijn WM. Wnt signaling in cardiac remodeling and heart failure. Handb Exp Pharmacol. 2017;243:371\u201393.","journal-title":"Handb Exp Pharm"},{"key":"1025_CR33","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/s41418-018-0187-3","volume":"26","author":"HH Seo","year":"2019","unstructured":"Seo HH, Lee S, Lee CY, Lee J, Shin S, Song BW, et al. Multipoint targeting of TGF-beta\/Wnt transactivation circuit with microRNA 384-5p for cardiac fibrosis. Cell Death Differ. 2019;26:1107\u201323.","journal-title":"Cell Death Differ"},{"key":"1025_CR34","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41569-019-0286-y","volume":"17","author":"KE Oatmen","year":"2020","unstructured":"Oatmen KE, Cull E, Spinale FG. Heart failure as interstitial cancer: emergence of a malignant fibroblast phenotype. Nat Rev Cardiol. 2020;17:523\u201331.","journal-title":"Nat Rev Cardiol"},{"key":"1025_CR35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1152\/physrev.00040.2017","volume":"99","author":"J van der Velden","year":"2019","unstructured":"van der Velden J, Stienen GJM. Cardiac disorders and pathophysiology of sarcomeric proteins. Physiol Rev. 2019;99:381\u2013426.","journal-title":"Physiol Rev"},{"key":"1025_CR36","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1002\/ehf2.13419","volume":"8","author":"N Hegemann","year":"2021","unstructured":"Hegemann N, Primessnig U, Bode D, Wakula P, Beindorff N, Klopfleisch R, et al. Right-ventricular dysfunction in HFpEF is linked to altered cardiomyocyte Ca2+ homeostasis and myofilament sensitivity. ESC Heart Fail. 2021;8:3130\u201344.","journal-title":"ESC Heart Fail"},{"key":"1025_CR37","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1161\/HYPERTENSIONAHA.109.141127","volume":"55","author":"P Malekar","year":"2010","unstructured":"Malekar P, Hagenmueller M, Anyanwu A, Buss S, Streit MR, Weiss CS, et al. Wnt signaling is critical for maladaptive cardiac hypertrophy and accelerates myocardial remodeling. Hypertension. 2010;55:939\u201345.","journal-title":"Hypertension"},{"key":"1025_CR38","doi-asserted-by":"publisher","first-page":"4645","DOI":"10.3390\/ijms22094645","volume":"22","author":"E Bogdanova","year":"2021","unstructured":"Bogdanova E, Beresneva O, Galkina O, Zubina I, Ivanova G, Parastaeva M, et al. Myocardial hypertrophy and fibrosis are associated with cardiomyocyte beta-catenin and TRPC6\/Calcineurin\/NFAT signaling in spontaneously hypertensive rats with 5\/6 nephrectomy. Int J Mol Sci. 2021;22:4645\u201361.","journal-title":"Int J Mol Sci"},{"key":"1025_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41401-018-0060-4","volume":"40","author":"WB Fu","year":"2019","unstructured":"Fu WB, Wang WE, Zeng CY. Wnt signaling pathways in myocardial infarction and the therapeutic effects of Wnt pathway inhibitors. Acta Pharmacol Sin. 2019;40:9\u201312.","journal-title":"Acta Pharmacol Sin"},{"key":"1025_CR40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/ejhf.1029","volume":"20","author":"TM Gorter","year":"2018","unstructured":"Gorter TM, van Veldhuisen DJ, Bauersachs J, Borlaug BA, Celutkiene J, Coats AJS, et al. Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20:16\u201337.","journal-title":"Eur J Heart Fail"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-01025-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-01025-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-01025-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T09:02:50Z","timestamp":1684746170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-01025-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1025"],"URL":"https:\/\/doi.org\/10.1038\/s41401-022-01025-y","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,6]]},"assertion":[{"value":"14 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there are no competing interests associated with the manuscript. ZZ, LW and SMA are employees of Guangzhou Curegenix, Co. Ltd. and Curegenix, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}